Nanoform partners with A&LS Pharma
Charlie Blackie-Kelly | October 2, 2025 | News story | Research and Development | A&LS Pharma, Nanoform
Distribution agreement will make Nanoform’s products available in South Korea
Nanoform Finland has entered into a distribution agreement with Ageing & Life Science Corp (A&LS), which will see its products become available in the South Korean market.
Under the agreement, the Seoul-based A&LS will act as Nanoform’s local partner, providing Korean pharmaceutical and biotech companies with access to Nanoform’s nanoparticle engineering technology. The deal focuses on Nanoform’s proprietary services, which can be applied to both small and large molecules to reduce clinical attrition and enhance drug molecule performance.
“We are thrilled to extend our Asian presence into South Korea, which is home to one of the world’s most dynamic and innovation-driven life science markets supported by significant government investment, a strong domestic pharmaceutical base, world-class biologics manufacturing capacity, and an active clinical trial ecosystem,” commented Christian Jones, chief commercial officer of Nanoform.
The partnership allows Nanoform to establish a footprint within the South Korean pharma market – a market valued at $28.83bn in 2024, with projected growth of 7.4% CAGR to 2030 and forecasts reaching $44.25bn annually, according to Nanoform.
“This environment creates unique opportunities for Nanoform to support companies in improving bioavailability, enhancing patient convenience and accelerating the development of next-generation therapies. Partnering with A&LS will build on Nanoform’s momentum in Japan and positions us to support a new wave of Korean innovators seeking to differentiate their products through our nanotechnology,” Jones added.
